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To the Editor 
Skin pigmentation is due to the accumulation of eumelanin, which is brown-black pigment and 
photoprotective, and pheomelanin, which is yellow-red pigment and may promote carcinogenesis 
(Valverde et al., 1995). The melanocortin-1 receptor (MC1R) gene regulates the amount and type 
of pigment production and is a major determinant of skin phototype (Garcia-Borron et al., 2005; 
Valverde et al., 1995). %LQGLQJRIĮ-PHODQRF\WHVWLPXODWLQJKRUPRQHĮ-MSH) to MC1R 
stimulates the enzymatic activity of adenylate cyclase enzyme, thereby elevating intracellular 
cyclic adenosine monophosphate (cAMP) levels. MC1R is a highly polymorphic, especially in 
Caucasian: more than 200 coding region variants have been described to date (Garcia-Borron et 
al., 2014; Gerstenblith et al., 2007; Perez Oliva et al., 2009). Six variants - D84E, R142H, 
R151C, I155T, R160W and D294H - have been designated DVµ5¶DOOHOHVGXHWRWKHLUstrong 
DVVRFLDWLRQZLWKWKHµUHGKDLUFRORU¶5+&SKHQRW\SHFKDUDFWHUL]HGE\red hair, fair skin, 
freckles and sun sensitivity. The V60L, V92M and R163Q variants are found to have a weaker 
association with the RHC phenotype and have been GHVLJQDWHGDVµU¶DOOHOHV (Garcia-Borron et 
al., 2014; Raimondi et al., 2008). 
Previous studies demonstrated that several alleles are associated with phenotypic characteristics 
and that MC1R variants are associated both with melanoma and non-melanoma skin cancer 
(NMSC) (Han et al., 2006; Pasquali et al., 2015; Scherer et al., 2008; Tagliabue et al., 2015) with 
a stronger role for darker-pigmented populations, suggesting that non-pigmentary pathways link 
MC1R with skin cancer development. Since the role and strength of each MC1R variant in 
determining specific phenotypic characteristics and the RHC phenotype remains unclear, we 
performed a pooled-analysis of individual-level data from the M-SKIP project, described in full 
elsewhere (Raimondi et al., 2012). We selected from the M-SKIP database all 5,366 cancer-free 
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controls with MC1R gene sequenced and information on at least one of the following phenotypic 
characteristics: hair color, eye color, skin type and freckles, thus including 16 independent 
studies from 18 publications (Table S1). 
We found greater Summary Odds Ratios (SORs) for carriers of two MC1R variants compared 
with carriers of only one variant allele (Table 1). Furthermore carriage of any MC1R variant, one 
variant and two or more variants, compared with not having such variants (i.e. wild-type (WT) 
subjects), were significantly associated with fair hair color, skin type I/II and presence of 
freckles. Red hair color was significantly associated with carrying any MC1R variant (SOR; 
95%CI: 3.54; 1.91-6.55) and with carrying two or more variants (SOR; 95%CI: 10.17; 5.28-
19.58), but not with carrying one MC1R variant (SOR; 95%CI: 1.18; 0.57-2.44). No significant 
association was observed for light eye color and MC1R. Sensitivity analyses indicated that the 
observed between-study heterogeneity may be attributable to single studies: when we excluded 
the studies that were outliers, we obtained similar pooled-ORs as the original ones, but no longer 
with evidence of heterogeneity (results not shown). No evidence of publication bias was found 
E\(JJHU¶VWHVW All the investigated MC1R variants compared with WT subjects were positively 
associated with skin type I/II and freckles (Table S2). The three variants that seemed to play the 
most important role in skin type determination and presence of freckles were D84E, R151C and 
D294H. Red hair color was significantly associated with all MC1R variants except for V92M and 
R163Q.  
We visualized the associations between hair color, eye color, skin type, freckles and the three 
main studied geographical areas by Multiple Correspondence Analysis (MCA) (Figure S1a/b). A 
two-dimension MCA solution, with Dimension 1 (Dim1) on the horizontal axis and Dimension 2 
(Dim2) on the vertical axis, was considered the most adequate because the first and second 
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dimension presented Benzecri-adjusted inertias of 85.31% and 11.31% respectively (Table S3), 
accounting for 96.62% of the total association. The extreme RHC phenotype (red-hair, skin type 
I and freckles) was associated either with carrying at least 2 MC1R variants (Figure S1a) or with 
the presence of major penetrant (µ5¶) alleles (Figure S1b). We suggest that Dim1 can be 
LQWHUSUHWHGDVD³SLJPHQWDWLRQVFRUH´EHFDXVHLWGLIIHUHQWLDWHVZHOOEHWZHHQGDUNDQGIDLU
phenotypic characteristics. The median pigmentation score increased with increasing number of 
MC1R variants, and for single MC1R variants it was higher (p<0.0001) compared with WT 
subjects (Figure S2). 
Seven of the nine MC1R variants analyzed in this study, V60L, D84E, R142H, R151C, I155T, 
R160W and D294H, are clearly hypomorphic with significant reduction in cAMP signaling 
potential (Beaumont et al., 2007; Herraiz et al., 2012; Kadekaro et al., 2010; Scott et al., 2002). 
Within this group of variants, the lowest SOR for red hair, skin type I/II or freckles corresponds 
to V60L. Interestingly, this variant was also the one with the smallest functional impairment in 
terms of coupling to the cAMP pathway, when the seven variants analyzed here were compared 
under identical experimental conditions (Herraiz et al., 2012).  
Results also showed that V92M and R163Q behave as µr¶ alleles, with a weak albeit significant 
association with cutaneous phenotypic traits. In heterologous systems, V92M has been reported 
to display either a slight functional impairment (Herraiz et al., 2012) or normal coupling to the 
cAMP pathway (Beaumont et al., 2007), whereas R163Q apparently signals as efficiently as WT. 
Therefore, it appears that the ability of V92M or R163Q to activate the cAMP pathway is 
similar, if not identical to WT. This suggests that other mechanisms account for their association 
with cutaneous phenotypic characteristics, for example,  V92M or R163Q might impair 
functional coupling to signaling module(s) different from the cAMP cascade. MC1R 
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promiscuously binds to a variety of intracellular partners with signaling potential and this ability 
might depend on WT conformation. However, little is known as to the effects of other variants 
on MC1R binding to its various protein partners, and the phenotypic consequences of such 
molecular interactions also remain largely unknown. Further research is needed to understand the 
scaffolding properties of MC1R, the functional consequences of the formation of signaling 
complexes orchestrated by the receptor, and the effects on these processes of the myriad of 
natural variants in the MC1R gene. 
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Table 1. Summary Odds Ratios for the association between combined MC1R variants and 
phenotypic characteristics 
Phenotypic characteristic MC1R studies/controls SOR (95% CI) I^2 (%) p-value3 
Hair color - fair vs. dark1 Wild-type 13/1371 1.00 (reference)   
 Any variant 13/2758 1.91 (1.38-2.65) 59 <0.01 
 1 variant 13/1991 1.55 (1.12-2.15) 39 0.07 
 2+ variants 13/767 3.32 (2.34-4.72) 62 <0.01 
Hair color - red vs. others Wild-type 7/705 1.00 (reference)   
 Any variant 7/1474 3.54 (1.91-6.55) 0 0.80 
 1 variant 7/1016 1.18 (0.57-2.44) 0 0.83 
 2+ variants 7/458 10.17(5.28-19.58) 0 0.77 
Eye color - fair vs. dark2 Wild-type 14/1530 1.00 (reference)   
 Any variant 14/2832 1.12 (0.96-1.30) 12 0.33 
 1 variant 14/2079 1.11 (0.94-1.32) 10 0.35 
 2+ variants 14/753 1.16 (0.93-1.45) 0 0.80 
Skin type - I, II vs. III, IV Wild-type 14/1540 1.00 (reference)   
 Any variant 14/3046 2.26 (1.81-2.83) 49 0.02 
 1 variant 14/2211 1.95 (1.51-2.53) 41 0.06 
 2+ variants 14/835 3.58 (2.68-4.78) 42 0.05 
Freckles - yes vs. no Wild-type 9/1067 1.00 (reference)   
 Any variant 9/2257 2.52 (1.99-3.20) 33 0.16 
 1 variant 9/1528 2.00 (1.52-2.64) 36 0.13 
 2+ variants 9/729 4.47 (3.25-6.15) 38 0.12 
SOR=Summary Odds Ratio, CI=Confidence Intervals. Note: significant ORs and p-values are in bold 
1Fair hair color were: red, blond, dark blonde, light brown. Dark hair color were: brown, black, dark brown. 2Fair 
eye color were: blue, green, grey, hazel. Dark eye color were: brown, black. 3Q test p-value 
 
 
 
